Immunology platform

Advanced immunoassays and inflammation models 

Our immunology team has developed an advanced immunoassay and inflammation platform that provides cutting-edge preclinical in vitro and in vivo/ex vivo models. Our scientists utilise comprehensive immunophenotyping, as well as biomarkers with pharmacodynamic, predictive and surveillance utility to accelerate the discovery, characterisation and optimisation of treatments and drug targets. This comprehensive approach enhances your immunology research and development initiatives across a broad range of therapeutic areas, including oncology, inflammation, cardiology and neurology. 

Detail of MACS Quant Flow Cytometer in action

Advanced spectral flow cytometry 

We utilise advanced spectral flow cytometry to comprehensively analyse immune cell markers and cytokines. This allows for complex immunophenotyping and identification of specialised subsets of B, T, NKT and NK cells, as well as dendritic cells, monocytes/macrophages and innate lymphocytes.  Minimal material is needed to extract detailed information from your samples. We offer established off-the-shelf panels for human (>30 parameters), murine (>28 parameters) and rat (>13 parameters) flow cytometry applications. We can also customise panels to your needs or develop new ones for other species, such as pigs or dogs. 

Comprehensive immunological profiling 

Our immunology platform offers a comprehensive array of methods and technologies to address your specific immunology-focused needs. Key applications include: 

  • Complex cytokine and immunophenotyping 
  • In-situ hybridisation (RNAscope) 
  • Precision protein analysis 
  • Single-cell sequencing 
  • Immuno-oncology in vivo models 
  • Immunohistochemistry and immunofluorescence assays, including spatial profiling 
  • Inflammation and Immunology in vivo models 
  • IncuCyte and confocal microscopy for image-based analyses.
 

Customised cell-based immunoassays 

The immune system involves a complex interplay of distinct cell types, cell subsets and genetic and environmental factors. To support your research, Nuvisan offers an extensive portfolio of single and complex co-culture systems for screening compounds, validating biomarkers, assessing immunogenicity, and determining mode-of-action (MOA). Key assays include: 

  • Human, rat and mouse whole blood and PBMC assays 
  • Assays based on distinct immune cell subsets (e.g., B cells, T cells, neutrophils, monocytes, macrophages, natural killer cells, dendritic cells) 
  • Differentiation and stimulation assays (e.g., Tregs, Th17, Th1, Th2, pDCs, mDCs, M1/M2 macrophages, B cell class switch) 
  • Ex vivo re-stimulation and proliferation assays 
  • Immune cell-mediated tumour-killing assays (2D and 3D)
  • Phagocytosis assays 
  • Migration assays.
 

Example of human whole blood- and PBMC-based assays with possible read-outs at NUVISAN

Related topics & resources

The “strings” of the heart that contract and relax with every beat.

Human stem cell platform

We are constantly expanding our hiPSC-derived cell portfolio in the cardiology and neurology indication spaces.

learn more
SimpleWestern assay in our laboratory

Our biomarker technology platform

Advance precision medicine with Nuvisan’s expertise in biomarker discovery, supporting the transition from drug discovery to clinical development.

learn more
Life cycle of a lymphocyte, highlighting its development and activation in the immune system.

Primary cell assays

Enhance drug development success with ex vivo tissue models, focusing on primary cell assays that provide translational value in drug discovery.

learn more
Let's connect

Want to discuss your project or have any questions?

 
v.1.1.1206